Recent
December 3, 2024
December 3, 2024
December 3, 2024
This issue highlights clinical advances in integrative medicine from the past year, and updates on trending industry topics. Included in this issue:
Presented by: Donald Abrams, MD
Delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis, was licensed and approved for the treatment of chemotherapy-induced nausea and vomiting in 1985. Due to the significant barriers to studying the potential therapeutic effects of the parent botanical, the medical literature does not support the strong anecdotal impression that cannabis itself is effective for this indication. Cannabis is also the only antiemetic agent that is also purported to be an appetite stimulant that is also a useful attribute in patients with malignant diagnoses.
This session will focus on the top 10 culinary herbs that are in everyone’s kitchen and how to use them for prevention and healing.
Presented by: Peter Bongiorno, ND, LAc
It is well known that post COVID syndrome includes a high percentage of patient experiencing neuropsychiatric symptoms, including delirium, depression, anxiety, and post-traumatic stress disorder (PTSD). This syndrome does have one typical factor among patients: COVID-19. However, that is where the similarity ends.
This presentation will explore a number of patient cases, highlighting predisposing factors, lab test findings and, of course, treatment strategies. The most important factors that predispose post-COVID patients to mental health illness will be identified – and provide a specific natural medicine protocols to use with patients.
Clostridia Bacterial Infections – More Than Just a Digestive System Problem
Understanding and Reversing True Causes of Chronic Joint Pain
Approaches to Utilizing Clinical Nutrigenomics in Practice
The Microbiome: A New Paradigm in Understanding Adverse Food Reactions
Managing type 2 diabetes is a complex process that requires a holistic approach tailored to patients’ individual lifestyles for continued compliance.
In this case report, experts work with a patient struggling to control her type 2 diabetes. Featuring expert perspectives from Mona Morstein, ND, Robert Silverman, DC, DACBN, DCBCN, MS, CCN, CNS, CSCS, CIISN, CKTP, CES, HKC, FAKTR, and Christine Arnholt, NBC-HWC, FMCHC, this report highlights nutrition, supplement, and lifestyle recommendations for addressing type 2 diabetes.
Presented by: Mark Houston, MD, MS, Msc, ABAARM, FAARM, FACP, FAHA, FASH, FACN, DABC
As the field of glycomics continues to expand, so does research into the endothelial glycocalyx, a glycan-based structure essential to vascular and systemic health. However, awareness of this important protective barrier in the blood vessels has not yet reached most clinicians. From hypertension to kidney disease, from atherosclerosis to neuropathy, the endothelial glycocalyx plays a decisive role in prevention, disease progression, and now, at last, treatment. This session provides an overview of this vital structure, recent research on the endothelial glycocalyx, and the therapeutics showing significant outcomes. This presentation will include new preliminary results from a neuropathy pilot study, in which the presenter is the lead principal investigator.